Fig. 1.
Kaplan–Meier plots stratified by prior bevacizumab use relative to time to progression (TTP); (A) and overall survival (OS); (B). Prior bevacizumab treatment is associated with a reduced TTP, but the difference was not statistically significant (P = .0627). Prior bevacizumab is associated with a significantly reduced OS (P = .0017).